STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 STI Update: Best Practices for Protecting Women’s Reproductive Health Heidi M. Bauer, MD MPH STD Control Branch, California Department of Public Health California STD/HIV Prevention Training Center October 27, 2011 Family PACT Webcast 1 Tools you can use – Feedback Toolbar Raise Hand Yes No Feedback Results Emoticons 2 Floating Toolbar Use the floating toolbar to communicate in today’s session. Participant List Q&A Drop Down Menu for additional options 3 1 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Q&A Click Send 4 File Transfer 2 Click File Name Press Download 1 5 STI Update: Best Practices for Protecting Women’s Reproductive Health Heidi M. Bauer, MD MPH STD Control Branch, California Department of Public Health California STD/HIV Prevention Training Center October 27, 2011 Family PACT Webcast 6 2 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Overview Prevention and Screening Chlamydia & Gonorrhea Cervicitis, Urethritis & Pelvic Inflammatory Disease Vaginitis: Trichomoniasis & Bacterial Vaginosis Viral STIs: Genital Warts & Herpes Syphilis 7 Risk Assessment: Women NEW question ◦ "Is it possible that any of your sex partners in the past 12 months had sex with someone else while they were still in a sexual relationship with you?" Douching may increase risk of BV, some STIs, and HIV CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 8 STD Screening for Women Sexually Active adolescents & up to age 25 Routine chlamydia and gonorrhea screening Others STIs and HIV based on risk Women over 25 years of age STI/HIV testing based on risk Pregnant women Chlamydia Gonorrhea (<25 years of age or risk) HIV Syphilis serology HepB sAg* Hep C (if high risk)* *Not a Family PACT benefit CDC 2010 STD Tx Guidelines www.cdc.gov/std/treatment 9 3 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Estimated Chlamydia Screening Coverage (HEDIS), Females 16–25, U.S.A. and California, 1999–2009 California National Source: National Committee on Quality Assurance; California DHCS Division of Medi-Cal Managed Care; Kaiser Permanente Northern CA; California DPH Office of Family Planning; CDPH STD Control Branch 10 Rev. 4/2009 10 Pregnancy Test Only (PTO) and Emergency Contraception (EC) visits are Missed Opportunities for CT/GC Screening Among FP clients ≤25 who were not tested for CT: 37% other visit types 63% PTO or EC visits *Only half of PTO clients were screened. Howard H et al. “Over 20 Study”, 9 clinics from 3 agencies, 2003-2005. Region IX IPP meeting, January 2010 11 Percent CT + Chlamydia Rates for Females <26 Screening vs. PTO Clients 20 18 16 14 12 10 8 6 4 2 0 Exam PTO 15% 12% 9% 7% 8% 4% IPP FP CA FP NC FP Infertility Prevention Project Title X clinics (CA, AZ, NE, PA, SC, VA), 1997-2005 Howard H et al. “Over 20 Study”, 9 clinics from 3 agencies, 2003-2005. N=4288 Geisler WM et al. Am J Ob Gyn. 2008:198:502. GC: 3%+ in women 16-25. N=1465 Chlamydia Screening Project Personal communication, A. Costello, Southern Nevada Health District , Title X Family Planning Program, Las Vegas NV, 2006 12 4 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Reducing missed opportunities for CT/GC screening: Staff training on guidelines Check lists and chart prompts Standing orders for EC & PTO visits Waiting room posters Trigger question on intake, history, & exam forms for all visit types Express visits for STI testing Signs on restroom doors 13 Chlamydia 14 Chlamydia, Gonorrhea, and Primary & Secondary Syphilis California Rates, 1990–2010 Chlamydia Rate per 100,000 population 400 400.0 (N=155,300) 300 200 Gonorrhea 100 P&S Syphilis 0 1990 '91 STD Control Branch '92 '93 '94 '95 '96 '97 '98 '99 2000 '01 '02 '03 '04 '05 '06 '07 '08 69.1 (N=26,840) 5.3 (N=2,059) '09 2010 Year Rev. 7/2011 15 5 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Chlamydia, Rates by Gender, California, 1990–2010 600 Rate per 100,000 population 500 Female 400 300 200 Male 100 0 1990 '91 '92 '93 '94 '95 '96 '97 '98 '99 2000 '01 '02 '03 '04 '05 '06 '07 '08 '09 2010 Year STD Control Branch Rev. 7/2011 16 Chlamydia, Rates by Gender and Age Group (in years) California, 2010 Male Rate per 100,000 3,000 2,000 1,000 Female 0 0 1,000 2,000 3,000 10-14 15-19 20-24 25-29 30-34 35-44 45+ Total STD Control Branch Note: Age was “Not Specified” for 0.3% of female cases and 0.3% of male cases for the given year. Since this disease is often asymptomatic, reported cases may reflect chlamydial infections identified through screening programs offered primarily to women. Rev. 7/2011 17 Chlamydia among Females Ages 15-24, Rates by County, California, 2010 STD Control Branch Rev. 7/2011 18 6 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Chlamydia Prevalence Monitoring, Percent Positive for Females by Age Group (in years) and Health Care Setting, California, 2010 25 23.7 15–19 20–24 25+ Percent Positive 20 15 10 8.3 6 5 4.5 3.8 STD Control Branch Managed Care Organization (2009 data) 8.1 6 5.6 1.9 0 13.7 13.2 6.5 5.4 5.3 4.6 2.3 Family Planning Clinics College Sites Teen Clinics School-Based Sites* Juvenile Detention* STD Clinics * These two venues target adolescents primarily. Source: California Department of Public Health, STD Control Branch; Los Angeles Infertility Prevention Project; and San Francisco Infertility Prevention Project Rev. 7/2011 19 Chlamydia Treatment Adolescents and Adults Recommended regimens (non-pregnant): Azithromycin 1 g orally in a single dose Doxycycline 100 mg orally twice daily for 7 days Recommended regimens (pregnant*): Azithromycin 1 g orally in a single dose Amoxicillin 500 mg orally TID x 7 days * Test of cure at 3-4 weeks only in pregnancy CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 20 Gonorrhea 21 7 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Gonorrhea, Rates by Gender, California, 1990–2010 Rate per 100,000 population 250 200 150 Male 100 Female 50 0 1990 '91 '92 '93 '94 '95 '96 '97 '98 '99 2000 '01 '02 '03 '04 '05 '06 '07 '08 '09 2010 Year STD Control Branch Rev. 7/2011 22 Gonorrhea, Rates by Gender and Age Group (in years), California, 2010 Male 300 Rate per 100,000 200 100 Female 0 0 100 200 300 10-14 15-19 20-24 25-29 30-34 35-44 45+ Total STD Control Branch Note: Gender “Not Specified” accounted for less than 0.5% of all cases. Rev. 7/2011 23 Gonorrhea, Rates by County, California, 2010 STD Control Branch Rev. 7/2011 24 8 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Gonorrhea, Female Rates by Race/Ethnicity and Age Group (in years), California, 2010 26 times white rate Rate per 100,000 1,500 1,200 STD Control Branch 900 600 Black 300 0 Hispanic White 10 - 14 15 - 19 20 - 24 25 - 29 30 - 34 Age Group 35 - 44 45+ Rev. 7/2011 25 Neisseria Gonorrhoeae Isolates with Alert Values or Decreased Susceptibility, CA GISP Data, 1990-2011* 12% 10% Azithromycin Cefpodoxime Cefixime & Cefpodoxime 8% Cefixime Percent of Isolates Ceftriaxone 6% 4% 2% 0% 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Year * 2011 data for January-June only Note: Cefpodoxime and cefixime alerts have MICs ≥ 0.25 µg/mL. Ceftriaxone alerts have MICs ≥ 0.125/mL. Azithromycin alerts have MICs ≥ 2.0/mL. STD Control Branch STD Clinic Sites: Orange, San Diego, San Francisco, Long Beach (ended participation in 2007), Los Angeles (added in 2003) 26 3 Changes to Gonorrhea Treatment in 2010 1. Ceftriaxone IM preferred over oral cephalosporins 2. Ceftriaxone dose increased to 250 mg 3. Dual treatment for chlamydia regardless of test result CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 27 9 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Gonorrhea Treatment Uncomplicated Genital/Rectal Infections Ceftriaxone 250 mg IM in a single dose PLUS* OR, if not an option: Cefixime 400 mg orally in a single dose Azithromycin 1 g orally or Doxycycline 100 mg BID x 7 days * Regardless of CT test result CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 28 Gonorrhea Treatment Alternatives Anogenital Infections ALTERNATIVE CEPHALOSPORINS: Single dose IM cephalosporin regimens or Cefpodoxime 400 mg orally once or Cefuroxime axetil 1 g orally once* PLUS Dual treatment with azithromycin 1 g or doxycycline 100 mg BID x 7 days, regardless of CT test result IN CASE OF ALLERGY: Azithromycin 2 g orally once (Caution: GI intolerance, emerging resistance) *Not a Family PACT benefit 29 Gonorrhea Treatment Oropharyngeal Infections Ceftriaxone 250 mg IM in a single dose IN CASE OF ALLERGY: Azithromycin 2 g orally once PLUS Azithromycin 1 g orally or Doxycycline 100 mg BID x 7 days CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 30 10 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Treatment Efficacy for Pharyngeal Gonorrhea DRUG AND DOSE Cefriaxone 125 mg IM EFFICACY 94% LIMITS / Ns L95%CI = 85.6% Ceftriaxone 250 mg IM 99% L95%CI = 94.0% Cefpodoxime 400 mg PO 70%, 26/37 patients Cefixime 400 mg PO 89%, 8/9 patients Cefixime + azithro 1 g PO 100%, 36/36 patients Azithromycin 2 g PO 95%, L95%CI = 76.2% 20/21 patients L. Newman, CDC STD Treatment Consultation Meeting 04/09 31 What to do if you suspect a cephalosporinrelated treatment failure: CULTURE: If GC culture not available on-site, call CA STD Control Branch for resources 510 620 3400 REPEAT TREATMENT: Ceftriaxone 500 mg IM PLUS Azithromycin 2 g orally in a single dose REPORT: To your local health department within 24 hours; call STD Control Branch if consult desired TREAT PARTNERS: All partners in last 60 days should be treated with CTX 500 mg + AZ 2g TEST OF CURE (TOC): Patient returns in 1 week for TOC with culture (if culture not avail, with NAAT) *if reinfection suspected, repeat tx with CTX 250 + AZ 1g See www.std.ca.gov for most current information 32 Preventing Repeat Infection: CT/GC Partner Treatment and Client Retesting 33 11 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Created by: California Department of Public Health (CDPH) Sexually Transmitted Disease (STD) Control Branch, San Francisco Department of Public Health STD 34 CT/GC Partner Management Options: Patient referral • Ask patient to notify partner and ensure treatment • Suggest patient bring partner to clinic for concurrent treatment (“BYOP”) • Internet-based anonymous notification Expedited partner treatment (EPT) • Patient-delivered partner treatment (PDPT)* • Health department field-delivered treatment • Pharmacy-based Provider or clinic-based referral Health department referral *PDPT covered only if the partner is an enrolled Family PACT client 35 The Effectiveness of Expedited Partner Treatment on Re-Infection Rates 20% GONORRHEA CHLAMYDIA P=.02 P=.17 15% 10% 5% 0% 13% 11% 11% 3% Usual Care EPT Usual Care EPT Golden M, et al. N Engl J Med 2005 Feb 17;352(7):676-85. 36 12 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 CT Partner Management Strategies Used in California FP Clinics Bring Your Own Partner “BYOP” Patient-Delivered Partner Treatment (PDPT) Patient Referral 14% 20% 54% 12% None/Unknown Yu Y-Y, et al. STD. Oct 2011. 37 Percent of Partners Treated by Management Strategy, California FP Clinics, 2005-2006 Yu Y-Y, et al. STD. Oct 2011. 38 CT/GC Partner Management Strategies Gaps: ▪ Not eliciting all partners ▪ Patient referral What works: Individualized partner treatment options Asking client to being partner to clinic (“BYOP”) Patient-delivered partner treatment (PDPT) 39 13 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 CT Rates Higher for Repeat Testing Compared with Screening, California FP clinics, 2008/2009 Percent positive Baseline Repeat Infection 18 16 14 12 10 8 6 4 2 0 15-19 20-25 26-30 31-35 >35 Age Group Source: Family PACT and Quest Diagnostics data Prepared by: CDPH STD Control Branch 40 Why is retesting for CT/GC important for women’s health? Repeat CT 6 infection leads to 5 higher risk of 4 Relative Risk complications: PID, ectopic pregnancy, Ectopic Pregnancy 3 2 1 infertility Pelvic Inflammatory Disease Most infections 0 1st 2nd 3rd Infection Infection Infection are asymptomatic Hillis SD, et al. (1997). Am J Obstet Gynecol 176(1 Pt 1): 103-7. 41 Retesting Recommendations: Retest all women and men with CT or GC 3 months after treatment If client returns earlier than 3 months, consider retest If client does not return for retesting at 3 months, retest when possible Test of cure is not recommended, except in pregnancy, compliance is in question, or symptoms persist CDC 2010 STD Tx Guidelines, www.cdc.gov/std/treatment 42 14 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Retesting Rates in California FP Clinics, 2007 Only ~1/3 of women treated for CT are retested within 6 months of treatment Surprisingly, another ~1/3 returned to clinic but were not retested These are missed opportunities! Returned and Retested Did not Return Returned but NOT Retested Chow J. Region IX Infertility Prevention Project Data (2007) 43 Strategies for Improving Retesting Counseling at treatment visit materials Protocols and chart prompts Express retesting visits Advance appointments Reminder systems: telephone, postcards, text message, email Home-based testing Written Downer SR et al Aust Health Rev 2006;30:389; Leong KC et al. Fam Pract 2006; 23:699. 44 CT/GC Management in a Nutshell: 1 Screen 2 Treat 3 Treat 4 Screen (Clients) (Partners) (3 months) 45 15 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 What’s New at the State? 46 InTOUCH: Texting and Home Testing to Improve Retesting www.intouch4health.org 47 “I Know” Campaign and Online Testing * www.dontthinkknow.org *Not a Family PACT benefit 48 16 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 “Partner Packs” PDPT Program Azithromycin distribution program started in 2007 54 California Title X agencies participating >35,000 doses distributed Increased routine use of PDPT Barandas A, California Family Health Council, 2010 Jotblad S et al. CDPH, in preparation 49 Coming soon… Free condoms: www.teensource.org Expanded clinic access sites GC “hot spots” 50 Cervicitis: Dx & Tx Diagnosis: Evaluate for PID, BV and trich Consider HSV Test for GC and CT Treat for chlamydia: • Age 25 or younger • STI risk: new/multiple partners, partner with other partners, unprotected sex • Follow-up unlikely Treat for gonorrhea if high prevalence (>5%) Treat BV if present 51 17 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Mycoplasma genitalium Sexually transmitted pathogen Associated with acute and persistent non-gonococcal urethritis (NGU) in men, endometritis in women Insufficient evidence for infertility, ectopic pregnancy, adverse birth outcomes • Diagnostic test in development • Azithro superior to doxy for M. genitalium urethritis: 82% vs 39% • Moxifloxacin effective for persistent NGU caused by M. genitalium 52 Urethritis Common Infectious Causes Bacterial STIs: ◦ GC 5-20% ◦ CT 15-40% Non-gonococcal urethritis (NGU) ◦ ◦ ◦ ◦ ◦ Mycoplasma genitalium 5-25% Ureaplasma 0-20%; data inconsistent Trichomonas vaginalis 5-20% HSV 15-30% Adenovirus, enterics, Candida, anaerobes 53 Urethritis Diagnosis Exam findings: o Purulent discharge Stat laboratory: o Gram stain exudate: 5 WBC/HPF or intracellular GNDC o Positive LE on urine dip o 10 WBCs/HPF on first void urine Laboratory tests: o GC and CT testing o Screen for syphilis, offer HIV CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 54 18 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Urethritis Treatment Initial episode, uncomplicated: Treat for both GC and CT unless GC ruled out Azithromycin efficacy better for M. genitalium Persistent infection: If noncompliance or re-infection, repeat treatment with standard therapy Consider trichomonas, doxy-resistant ureaplasma, prostatitis, non-infectious etiologies CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 55 Persistent NGU Treatment Recommended regimens: Metronidazole 2 g orally in a single dose OR Tinidazole 2 g orally in a single dose PLUS Azithromycin 1 g orally in a single dose (if not used for initial episode) Moxifloxacin 400 mg PO x 7d effective for NGU treatment failures due to M. genitalium* *Not a Family PACT benefit CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 56 Pelvic Inflammatory Disease (PID) Some association with M. genitalium ◦ Insufficient data to support testing/treatment for MG No change in criteria for diagnosis or hospitalization Minimum Clinical Criteria: o Uterine tenderness OR o Adnexal tenderness OR o Cervical motion tenderness 57 19 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 PID Treatment Issues Emergence of QRNG ◦ Quinolones not recommended ◦ If parenteral treatment not feasible and GC prevalence and individual risk low, FQs may be considered Limited data: Ceftriaxone 250 mg IM + azithro 1g PO q wk x 2 No oral cephalosporins are recommended When to use metronidazole: ◦ Oral regimens only ◦ Assess for BV and if present, use metronidazole ◦ If no wet mount available, use metronidazole Insufficient evidence to warrant removal of IUD CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 58 PID: Oral Treatment Regimens Oral regimens: Ceftriaxone 250 mg IM (or other parenteral 3rd generation cephalosporin) x 1 or Cefoxitin 2 g IM with probenecid 1 g orally once PLUS Doxycycline 100 mg orally twice daily for 14 days WITH OR WITHOUT Metronidazole 500 mg orally twice daily for 14 days CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 59 PID: Parenteral Regimens* *Not a Family PACT benefit Parenteral regimen A: Continued for 24 hours after clinical improvement, Cefoxitin 2 g IV q6h or Cefotetan 2 g IV q12h plus Doxycycline 100 mg IV or PO q12h Then Doxycycline 100 mg PO BID for total of 14 d Parenteral regimen B: Clindamycin 900 mg IV q8h plus Gentamicin loading dose (2 mg/kg) IV or IM followed by maintenance dose (1.5 mg/kg q8h) Then Doxycycline 100 mg PO BID or Clindamycin 450 mg PO QID for total of 14 d CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 60 20 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Trichomoniasis Diagnostic testing: ◦ Aptima TV (NAAT) recently approved ◦ POC tests (Affirm VP III, OSOM Trich Rapid Test*) ◦ Trich on Pap may need confirmation, liquid cytology more specific Consider selective screening Consider retesting women 3 months after treatment Antimicrobial resistance significant (5-10%) Treat all recent sex partners; consider EPT *Not a Family PACT benefit CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 61 Trichomonas Screening? Screening rationale is based on: High prevalence (STD clinics and other settings) Selected high risk patients Association with adverse health outcomes Availability of NAAT (GenProbe Aptima ASR) Controversies about screening: No evidence that screening and treatment improves health outcomes Expense 62 Trichomoniasis Testing and Screening Recommendations Test women with vaginal discharge Screening recommended for HIV+ women Consider screening in those at high risk for infection: ◦ ◦ ◦ ◦ new or multiple partners history of STIs exchange sex for payment use injection drugs Consider retest in 3 months NAATs preferred test for males CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 63 21 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Prevalence of T. vaginalis by Race/Ethnicity, U.S. Women aged 14-49, NHANES 2001-2004 13.3% 14 12 10 8 6 4 3.1% 1.3% 2 1.8% 0 Overall White Hispanic Black Sutton M et al. Clin Infect Dis 2007; 15 (10):1319-26 64 Trichomoniasis Treatment Recommended regimen: Metronidazole 2 g PO x 1 Tinidazole 2 g po x 1 Consider treating HIV-infected women: Metronidazole 500 mg PO BID x 7d Alternative regimen: Metronidazole 500 mg PO BID x 7d Recommended regimen in pregnancy: Metronidazole 2 g PO x 1 Note: Vaginal therapy is ineffective Tinidazole is a Category C drug in pregnancy CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 65 Trichomoniasis Treatment Failure First treatment failure, re-treat with: Metronidazole 500 mg PO BID x 7 days If repeat failure, treat with: Metronidazole 2 g PO x 5 days Tinidazole 2 g PO x 5 days Susceptibility testing: send isolate to CDC CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 66 22 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Bacterial Vaginosis (BV) Additional alternative treatment regimens Insufficient evidence to support screening high risk pregnant women; against screening in low risk (USPSTF) Pre-procedural screening/treatment not recommended Prevention: use condoms, avoid douching 67 BV Treatment Recommended regimens: Metronidazole 500 mg PO BID x 7 d Metronidazole gel 0.75% 5 g per vagina QD/BID x 5 d Clindamycin cream 2% 5 g per vagina QHS x 7 d Alternative regimens: Tinidazole 2 g PO QD x 2 days Tinidazole 1 g PO QD x 5 days Clindamycin 300 mg PO BID x 7 d Clindamycin ovules 100 mg per vagina QHS x 3 d Recurrences: Metronidazole gel 2x weekly x 4-6 weeks Oral nitroimidazole followed by intravaginal boric acid and suppressive metronidazole gel* *Not a Family PACT benefit CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 68 New Genital Wart Treatment Sinecatechins (Veregen) a green tea extract ointment (strengths 15% and 10%) approved for treatment of genital warts* Cost $287 for 15 grams Not recommended in pregnancy, HIV, HSV *Not a Family PACT benefit 69 23 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Efficacy of Sinecatechins Randomized double-blind placebo controlled trial of N=502 patients with 2-30 warts each Applied ointment three times a day for 16 weeks or until clearance of all warts 100% Complete Clearance Partial Clearance 80% 60% 40% 20% 0% 78% 57% 52% 34% Sinecatechin Placebo Sinecatechin Placebo Tatti S et al, Obstet Gynecol. 2008 Jun;111(6):1371-9 70 Genital Herpes Testing: ◦ Culture, PCR for lesions ◦ Type-specific serology ◦ IgM testing not useful Added for episodic treatment: Suppressive therapy: prevents outbreaks and transmission Stronger recommendation for antiviral treatment in late pregnancy Famciclovir 500 mg PO x 1, then 250 mg BID x 2 d* *Not a Family PACT benefit 71 Herpes Serology*: Recommendations Type-specific HSV-2 serology tests may be useful: ◦ Recurrent/atypical symptoms with negative culture ◦ Clinical diagnosis without lab confirmation ◦ Patients with a partner with genital HSV Some experts recommend serology tests: ◦ Patients who request testing or as part of “comprehensive STI evaluation” ◦ Patients with multiple partners, HIV-infected, MSM at high HIV risk Universal screening NOT recommended *Not a Family PACT benefit CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 72 24 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Genital Herpes Treatment Issues All patients with initial genital HSV should receive treatment Episodic therapy for recurrent HSV: ◦ Added Famciclovir 500 mg PO x 1, then 250mg BID for 2 days Famciclovir is less effective for suppressive therapy than acyclovir and valacyclovir Suppressive HSV therapy does not reduce the risk of HIV in HSV-2 infected individuals Antiviral therapy recommended late in pregnancy in women with symptomatic HSV to reduce Csections CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 73 Syphilis Screening: MSM, HIV+, pregnancy Diagnosis: Reverse serology screening challenges Treatment: no extra dose of BIC for primary, secondary, and early latent syphilis in HIV-infected patients CSF evaluation: only for neuro symptoms, tertiary syphilis, or serology treatment failure 74 Primary & Secondary Syphilis, Cases by Gender California, 1996–2010 P&S Syphilis Rates, 1940-2010, California 2,250 Number of Cases 1,750 1,500 Rate per 100,000 2,000 ALL MALE 75 50 25 0 1940 1950 1960 1970 1980 1990 2000 2010 Year MEN WHO HAVE SEX WITH MEN 1,250 1,000 750 500 250 FEMALE 0 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 STD Control Branch Year Rev. 7/2011 75 25 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Primary & Secondary Syphilis, Rates by County California, 2010 STD Control Branch Rev. 7/2011 76 Syphilis Reverse Serology Screening Treponemal tests Non-treponemal tests (i.e., EIA, CLIA) reflex to • SPECIFIC TO TP • QUALITATIVE • REACTIVITY PERSISTS OVER LIFETIME (i.e. RPR, VDRL) • NOT SPECIFIC TO TP • QUANTITATIVE • REACTIVITY DECLINES WITH TIME CHALLENGES: • Cannot distinguish between active/old disease (treated/untreated) • Confusion re: management of patients with discrepant serology 77 Reverse Serology Testing Algorithm Treponemal Test (EIA/CLIA) + - No infection, Early infection or False Negative Quantitative Non‐trep Test (RPR, VDRL) - + 2nd Trep Test (TP‐PA) Probable false positive EIA If high risk: repeat trep EIA (and RPR if EIA still+) INFECTION: old vs. new + INFECTION: old vs. late/early untreated Assess for hx of treated syphilis, sx/signs If treated, no further action If untreated, consider rx for latent syphilis If low risk, consider repeat trep EIA in 1 month (and RPR if EIA still +) 78 26 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 Syphilis Treatment Primary, Secondary & Early Latent: Benzathine penicillin G 2.4 million units IM in a single dose Late Latent and Unknown Duration: Benzathine Penicillin G 7.2 million units total, given as 3 doses of 2.4 million units each at 1 week intervals Neurosyphilis: Aqueous Crystalline Penicillin G 18-24 million units IV daily administered as 3-4 million IV q 4 hr for 10 -14 d No enhanced efficacy of additional doses of BPG, amoxicillin or other antibiotics even if HIV infected CDC 2010 STD Treatment Guidelines www.cdc.gov/std/treatment 79 Online STD Resources CDC Treatment Guidelines www.cdc.gov/std/treatment California STD/HIV Prevention Training Center www.stdhivtraining.org California Department of Public Health STD Control Branch www.std.ca.gov 80 Planned Parenthood Regina in Saskatchewan, Canada 81 27 STI Update: Best Practices for Protecting Women's Reproductive Health October 27, 2011 QUESTIONS? 82 Evaluation and Other Forms At the conclusion of session complete: 1. Evaluation Form 2. Sign-in Sheet 3. Continuing Education Forms (if applicable) o Post-Test o CE Application Forms can be downloaded at the end of this session by file transfer. Those without web access can get forms by calling 1-877- FAMPACT Thank You! 83 28
© Copyright 2024